Key statistics dashboard for None (ALLR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics.
Valuation Multiples
| P/E Ratio | -1.42 |
| Price / Book | 4.99 |
| P/S | 51.19 |
| P/FCF | -1.28 |
Profitability
| Gross Margin | 107.54% |
| EBIT Margin | -3195.07% |
| EBITDA Margin | -3213.04% |
| Operating Margin | -3128.99% |
| Net Margin | -3575.07% |
Financial Health
| Current Ratio | 1.11 |
| Quick Ratio | 1.11 |
| Cash Ratio | 0.59 |
| Debt / Equity | 6.30 |
| Debt / Assets | 69.39% |
| Interest Coverage | -10.15 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -10.51 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | 0.22 |
| Cash per share | 1.07 |
| FCF per share | -0.87 |
| Tangible Book Value per share | 0.22 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 0.50 |